EW · 10-Q · 2026Q3 · Full report

Operating Cash Flow and Capex

Edwards Lifesciences Corp · 2026-11-04 · Importance 47 · Surprise 22 · In source text

Operating cash flow for the nine months ended September 30, 2026 was $1,266.0 million, up $121.7 million from the prior-year period, primarily because tax payments were lower, partly offset by higher working-capital needs. Investing activities used $542.4 million, including $249.7 million of net investment purchases and $195.4 million of capital expenditures. Capital expenditures increased from $162.8 million in the comparable 2025 period. Financing activities used $552.3 million, primarily reflecting $714.0 million of treasury-stock purchases, partly offset by $159.2 million of stock-plan proceeds.

Key facts

• Edwards Lifesciences’ operating cash flow was $1,266.0 million for the nine months ended September 30, 2026, up $121.7 million year over year, primarily due to lower tax payments, partly offset by higher working capital needs. source
• Edwards Lifesciences used $542.4 million in investing activities in the nine months ended September 30, 2026, including $249.7 million net investment purchases, $195.4 million capital expenditures, $55.2 million notes receivable, and $33.7 million net business-combination payments. source
• Edwards Lifesciences used $514.6 million in investing activities in the nine months ended September 30, 2025, including $198.5 million net investment purchases, $162.8 million capital expenditures, $93.4 million notes receivable, $36.3 million for a Critical Care sale working-capital adjustment, and $19.6 million for acquisition options. source
• Edwards Lifesciences’ 2025 nine-month tax payments included $160.0 million of local taxes associated with the Critical Care sale and higher U.S. repatriation, federal, and state estimated tax payments. source

Impact estimates